


Healthcare Industry News: HIV/AIDS
News Release - June 15, 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Source: Gilead Sciences
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
